Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 20/20 | 0.61 |
| ▸ | FABP1 | P07148 | 4/20 | 0.49 |
| ▸ | HSD17B13 | Q7Z5P4 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | THRB | P10828 | 1/20 | 0.49 |
| ▸ | LIFR | P42702 | 1/20 | 0.49 |
| ▸ | RECQL | P46063 | 1/20 | 0.49 |
| ▸ | BLM | P54132 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | FXR2 | P51116 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12188629 | 0.95 | NR1H4 (0.56) | NR1H4FABP1HSD17B13MEN1THRB | |
| SCHEMBL12168847 | 0.89 | NR1H4 (0.64) | NR1H4FABP1HSD17B13MEN1THRB | |
| SCHEMBL12188480 | 0.82 | NR1H4 (0.65) | NR1H4FXR2 | |
| SCHEMBL16230432 | 0.82 | NR1H4 (0.41) | NR1H4FABP1HSD17B13 | |
| SCHEMBL19628521 | 0.81 | NR1H4 (0.67) | NR1H4FABP1HSD17B13FXR2 | |
| SCHEMBL12168874 | 0.81 | NR1H4 (0.61) | NR1H4FABP1HSD17B13MEN1THRB | |
| SCHEMBL12168859 | 0.80 | NR1H4 (0.71) | NR1H4FABP1HSD17B13MEN1THRB | |
| SCHEMBL12168830 | 0.79 | NR1H4 (0.65) | NR1H4FABP1HSD17B13MEN1THRB | |
| SCHEMBL19230543 | 0.79 | NR1H4 (0.81) | NR1H4FABP1HSD17B13MEN1THRB | |
| SCHEMBL12188533 | 0.78 | NR1H4 (0.63) | NR1H4FABP1HSD17B13MEN1THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8952042-B2 | FXR (NR1H4) binding and activity modulating compounds | PHENEX PHARMACEUTICALS AG (DE) | 2015-02-10 | — | — | US | disclosed |
| EP-2467366-B1 | NOVEL FXR (NR1H4) BINDING AND ACTIVITY MODULATING COMPOUNDS | PHENEX PHARMACEUTICALS AG (DE) | 2014-11-12 | — | — | EP | disclosed |
| US-20120232116-A1 | NOVEL FXR (NR1H4) BINDING AND ACTIVITY MODULATING COMPOUNDS | PHENEX PHARMACEUTICALS AG (DE) | 2012-09-13 | — | — | US | disclosed |
| WO-2011020615-A1 | NOVEL FXR (NR1H4 ) BINDING AND ACTIVITY MODULATING COMPOUNDS | PHENEX PHARMACEUTICALS AG (DE) | 2011-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120232116-A1 | NOVEL FXR (NR1H4) BINDING AND ACTIVITY MODULATING COMPOUNDS | NR1H4, NR1H2, NR1H3 | NR1H4 1/4885FABP1 31/4885HSD17B13 504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.